Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Co-Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CODX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CODX's weekly volatility has decreased from 36% to 15% over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CODX exceeded the US Medical Equipment industry which returned 19% over the past year.
Return vs Market: CODX exceeded the US Market which returned 22.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Co-Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StCo-Diagnostics, Inc. (NASDAQ:CODX) Analysts Are Reducing Their Forecasts For Next Year
1 month ago | Simply Wall StWhat Can We Make Of Co-Diagnostics' (NASDAQ:CODX) CEO Compensation?
2 months ago | Simply Wall StIs Co-Diagnostics, Inc.'s (NASDAQ:CODX) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CODX ($11.04) is trading below our estimate of fair value ($23.87)
Significantly Below Fair Value: CODX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CODX is good value based on its PE Ratio (9.4x) compared to the US Medical Equipment industry average (49.9x).
PE vs Market: CODX is good value based on its PE Ratio (9.4x) compared to the US market (19.4x).
Price to Earnings Growth Ratio
PEG Ratio: CODX is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: CODX is overvalued based on its PB Ratio (5.9x) compared to the US Medical Equipment industry average (4.4x).
How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CODX's forecast earnings growth (14.9% per year) is above the savings rate (2.2%).
Earnings vs Market: CODX's earnings (14.9% per year) are forecast to grow slower than the US market (21.9% per year).
High Growth Earnings: CODX's earnings are forecast to grow, but not significantly.
Revenue vs Market: CODX's revenue (20.7% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: CODX's revenue (20.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time
How has Co-Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CODX has a high level of non-cash earnings.
Growing Profit Margin: CODX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CODX has become profitable over the past 5 years, growing earnings by 32.5% per year.
Accelerating Growth: CODX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CODX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).
Return on Equity
High ROE: CODX's Return on Equity (52.9%) is considered outstanding.
How is Co-Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: CODX's short term assets ($51.9M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: CODX's short term assets ($51.9M) exceed its long term liabilities ($60.0K).
Debt to Equity History and Analysis
Debt Level: CODX is debt free.
Reducing Debt: CODX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: CODX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CODX has no debt, therefore coverage of interest payments is not a concern.
What is Co-Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CODX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CODX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CODX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CODX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CODX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dwight Egan (67 yo)
Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan serves as President, Chief Executive Officer an...
CEO Compensation Analysis
Compensation vs Market: Dwight's total compensation ($USD460.00K) is below average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.
|Chairman||no data||US$460.00k||no data|
|Independent Director||3.58yrs||US$72.75k||0.060% |
|Independent Director||1.33yrs||US$45.83k||0% |
|Independent Director||1.5yrs||US$45.25k||0.035% |
|Independent Director||1.5yrs||US$29.75k||0% |
Experienced Board: CODX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 63%.
Co-Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Co-Diagnostics, Inc.
- Ticker: CODX
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$306.438m
- Shares outstanding: 28.27m
- Website: https://www.codiagnostics.com
Number of Employees
- Co-Diagnostics, Inc.
- 2401 South Foothill Drive
- Suite D
- Salt Lake City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CODX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jul 2017|
|C97||MUN (Boerse Muenchen)||Yes||Common Stock||DE||EUR||Jul 2017|
|C97||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2017|
|0A50||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 2017|
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/04 23:02|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.